Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
LeqvioⓇ adoption expanding as we progress the launch
GROWTH
LEQVIO®
Addressing non-clinical barriers in US
Adoption
Adoption
Facilities having ordered LeqvioⓇ
HCPS2 with LeqvioⓇ experience
US LeqvioⓇ launch tracking EntrestoⓇ
US sales evolution
USD m
50
+29%
+33%
40
30
EntrestoⓇ
20
LeqvioⓇ
2,200
9,600
10
1,400
1,700
7,200
4,800
0
6
12
18
24
30
30
36
Q3 2022
Q4 2022 Q1 2023
Q3 2022 Q4 2022
Q1 2023
Months since launch
Access
Adherence
Patients covered
Patients coming for
at or near label³
76%
2nd dose within
<95 days4
75%
Global sales evolution
USD m
64
Ex-US
US
42
34
22
14
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
HCP
healthcare professional.
*Leqvio® is administered initially, again at 3 months, and then
1. Either an alternate site of care or a physician practice. 2. Either prescribe LeqvioⓇ to a patient based on service center data, data on file or have ordered through Free Trial Offer program.
3. As of April 10, 2023. 4. Refers to average duration in between doses. Based on IQVIA and data shared by infusion management and ambulatory infusion center companies.
once every 6 months. Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam Pharmaceuticals.
17 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation